As such, Beg et al. noted that the observed toxicity with MRX34 (i.e., pneumonitis, colitis) showed similarity with immune-related adverse events (irAEs) during ICI therapy [77], and Van Zandwijk et al. reported an inverse relationship between the efficacy of miR-16 and PD-L1 expression on mesothelioma cells and speculated whether the response to ICIs could be augmented by the combination with a miR-16 mimic [78]. This evidence concerns the gene CD274 and mesothelioma.